The Influenza Partnering provides understanding and access to the influenza partnering deals and agreements entered into by the worlds leading healthcare companies
This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in October 2014.
Current Partnering releases its first update of the article previously published last year on the most partnered therapeutic trends in pharma. The article analyses the most partnered therapeutic targets of 2009-2014 and identifies the areas that have gained in popularity since last year and the new areas that have entered the list
Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.
Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity
Gilead Sciences is a top pharmaceutical company based in California, USA
Sorry, your search returned no results.
Under the flu-mAb collaboration, Crucell and Ortho-McNeil-Janssen Pharmaceuticals or its affiliates will share responsibilities to develop a universal flu-mAb product targeting all influenza A strains, including H1N1 strains (which cause seasonal flu and the current pandemic) and the H5N1 or avian strain (‘bird flu’).
Under the agreement, which was signed recently at WHO headquarters in Geneva, Nobilon has granted WHO a non-exclusive license to develop, register, manufacture, use and sell seasonal and pandemic live, attenuated, influenza vaccines (LAIV), produced on embryonated chicken eggs.
Merck is investing $30 million in a Series B round of financing for Visterra.
Big pharma, Baxter International has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer for a total cash consideration of $635 million, subject to certain adjustments.